Nature Reviews Drug Discovery Q1 Unclaimed

Nature Publishing Group United Kingdom
Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Nature Reviews Drug Discovery is a monthly journal aimed at everyone working in the drug discovery and development arena. In addition to the highest-quality reviews and perspectives covering a broad scope, each issue includes news stories that investigate the hottest topics in drug discovery, timely summaries of key primary research papers, and concise updates on the latest advances in areas such as new drug approvals, patent law and emerging industry trends and strategies. It has an SJR impact factor of 9,921.

Nature Reviews Drug Discovery focuses its scope in these topics and keywords: drug, strategies, drugs, clinical, antibodies, cancer, human, therapeutic, court, competitioncombating, ...

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy: Non Open Access

Type of publications:

Publication frecuency: -

Price

- €

Inmediate OA

- €

Embargoed OA

0 €

Non OA

Metrics

Nature Reviews Drug Discovery

9,921

SJR Impact factor

328

H Index

247

Total Docs (Last Year)

676

Total Docs (3 years)

7946

Total Refs

8550

Total Cites (3 years)

314

Citable Docs (3 years)

12,38

Cites/Doc (2 years)

32,17

Ref/Doc

Aims and Scope


drug, strategies, drugs, clinical, antibodies, cancer, human, therapeutic, court, competitioncombating, cureupcoming, deconvolution, directionspde, discovery, discoverycan, disease, diseasesflipping, class, catalysts, candidateserratum, antiepileptic, applications, approach, approaches, barrierin, biosimilar, biosimilarstwo, bispecific, blood, brain, briefmicrobubbles,



Best articles by citations

Overcoming inhibition

View more

Neuropeptide gene polymorphisms and human behavioural disorders

View more

Biodegradable multi-drug dispenser

View more

How Goldilocks is partial to dopamine receptors

View more

FDA approves first-in-class SYK inhibitor

View more

Lighting up targets with reporter ribozymes

View more

Hitting the MARCKS

View more

Regulating the beat

View more

When drugs unintentionally affect gut bugs

View more

Getting the measure of stroke

View more

Paralyzing the two-faced BOTOX

View more

New forms of attack

View more
SHOW MORE ARTICLES

Betting on biogenerics

View more

BACE failures lower AD expectations, again

View more

Mining for bioinformatics jobs

View more

Birds of a feather...

View more

Certolizumab pegol

View more

Correction: Cox-2 and beyond: Approaches to prostagland in inhibition in human disease

View more

Challenges and opportunities in animal drug development: a regulatory perspective

View more

Legless - but still the way forward

View more

Scientists slam rationale behind largest HIV vaccine trial

View more

Targeting the Nogo Receptor to Treat Central Nervous System Injuries

View more

Engineering a smoother ride

View more

Shedding light on a silent pathway

View more

Comments

No comments ... Be the first to comment!

FAQS